trial

Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)

NCTId NCT01822418
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 27 (actual)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
27 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-01
Primary completion
2015-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
agomelatine

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor
ServierCollaborator

Investigators

1
Mathias Zink, MDPrincipal Investigator

Sites

1 total
Mannheim, Germany

Facts & assertions

4 sourced
Enrollment
27
Phase
PHASE4
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
agomelatine
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
collaborator
Servier
company
indication
Schizoaffective Disorder
indication
Schizophrenia, Paranoid
indication
Psychotic Disorders
indication
investigator
Mathias Zink, MD
person